Market revenue in 2023 | USD 2,136.9 million |
Market revenue in 2030 | USD 3,580.9 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Frozen nondonor |
Fastest growing segment | Fresh Donor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Fresh Nondonor, Frozen Nondonor, Fresh Donor, Frozen Donor |
Key market players worldwide | Bayer AG, Cook Medical, Merck KGaA, Ferring, FUJIFILM Holdings Corp, Genea Biomedx, Merck & Co Inc, The Cooper Companies Inc, Thermo Fisher Scientific Inc, Vitrolife AB ADR, Boston Scientific Corp, Nova IVF, Fortis Healthcare, RMA Network, TFP Fertility Group, US Fertility |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to in vitro fertilization market will help companies and investors design strategic landscapes.
Frozen nondonor was the largest segment with a revenue share of 48.44% in 2023. Horizon Databook has segmented the China in vitro fertilization market based on fresh nondonor, frozen nondonor, fresh donor, frozen donor covering the revenue growth of each sub-segment from 2018 to 2030.
The reduce the single child law is expected to drive market growth, as well as increase the number of people traveling abroad to avail these treatments. China has one of the largest IVF markets globally. The demand for fertility treatments, including IVF, has been increasing due to factors such as delayed marriages, rising infertility rates, and a growing awareness of assisted reproductive technologies.
China currently has 539 public & private IVF facilities, and the National Health Commission (NHC) set a goal to establish one IVF facility for every 2.3 million people in the country by 2025. This ambitious plan would increase the total number of IVF facilities in China to over 600.
The aim of expanding the number of IVF facilities is to improve accessibility to fertility treatments for individuals and couples across the country. By increasing the availability of IVF services, the government of China hopes to address fertility issues, promote reproductive health, and support individuals in their desire to start or expand their families.
Horizon Databook provides a detailed overview of country-level data and insights on the China in vitro fertilization market , including forecasts for subscribers. This country databook contains high-level insights into China in vitro fertilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account